MT-ATP8 Rabbit pAb
MT-ATP8 Rabbit pAb from ELK Biotechnology Read more ›

Product Description
MT-ATP8 Rabbit pAb is an ELK Biotechnology antibody for research workflows involving MT-ATP8.
Background
disease:Defects in MT-ATP6 are a cause of infantile bilateral striatal necrosis [MIM:500003]. Bilateral striatal necrosis is a neurological disorder resembling Leigh syndrome.,disease:Defects in MT-ATP6 are a cause of Leber hereditary optic neuropathy (LHON) [MIM:535000]. LHON is a maternally inherited disease resulting in acute or subacute loss of central vision, due to optic nerve dysfunction. Cardiac conduction defects and neurological defects have also been described in some patients. LHON results from primary mitochondrial DNA mutations affecting the respiratory chain complexes.,disease:Defects in MT-ATP6 are a cause of Leigh syndrome (LS) [MIM:256000]. LS is a severe neurological disorder characterized by bilaterally symmetrical necrotic lesions in subcortical brain regions.,disease:Defects in MT-ATP6 are the cause of neurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP) [MIM:551500].,disease:Defects in MT-CO3 are a cause of cytochrome c oxidase deficiency (COX deficiency) [MIM:220110]; also called mitochondrial complex IV deficiency. COX deficiency is a clinically heterogeneous disorder. The clinical features are ranging from isolated myopathy to severe multisystem disease, with onset from infancy to adulthood.,disease:Defects in MT-CO3 are a cause of Leber hereditary optic neuropathy (LHON) [MIM:535000]. LHON is a maternally inherited disease resulting in acute or subacute loss of central vision, due to optic nerve dysfunction.
Additional antibody information
| Specificity | This antibody detects endogenous levels of human MT-ATP8 |
|---|---|
| Validation evidence captions | Immunohistochemical analysis of paraffin-embedded human cervical carcinoma. 1, Antibody was diluted at 1:200(4° overnight). 2, Tris-EDTA,pH9.0 was used for antigen retrieval. 3,Secondary antibody was diluted at 1:200(room temperature, 45min). |
Key Facts
| Target | MT-ATP8 |
| Also known as | ATP synthase protein 8 (A6L;F-ATPase subunit 8) |
| Concentration | 1 mg/ml |
| Working concentration | IHC-p 1:50-200, ELISA(peptide)1:5000-20000 |
| Species reactivity | Human;Rat;Mouse; |
| Cellular localization | Mitochondrion membrane; Single-pass membrane protein. |
| Purity | The antibody was affinity-purified from mouse ascites by affinity-chromatography using specific immunogen. |
| Form / buffer | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Research area | >>Oxidative phosphorylation;>>Metabolic pathways;>>Thermogenesis;>>Alzheimer disease;>>Parkinson disease;>>Amyotrophic lateral sclerosis;>>Huntington disease;>>Prion disease;>>Pathways of neurodegeneration - multiple diseases;>>Chemical carcinogenesis - reactive oxygen species;>>Diabetic cardiomyopathy |
| Host species | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Conjugation | Unconjugated |
| Tested applications |
IHCELISA |
| Dilution range | IHC-p 1:50-200, ELISA(peptide)1:5000-20000 |
| Immunogen | Synthesized peptide derived from human MT-ATP8 AA range: 30-110 |
| Purification | The antibody was affinity-purified from mouse ascites by affinity-chromatography using specific immunogen. |
Reactivity & Application Validation
3 speciess| Species | WB | IHC | IF | ELISA | IP | FCM | CHIP |
|---|---|---|---|---|---|---|---|
| Human | |||||||
| Rat | |||||||
| Mouse |
| Species | Dilution | Notes |
|---|---|---|
| Human | IHC-p 1:50-200 | — |
| Rat | — | — |
| Mouse | — | — |
| Species | Dilution | Notes |
|---|
Specifications
Storage & Stability
Compliance & Certifications
Manufactured under ISO 9001:2015 quality management standards.
Not intended for diagnostic or therapeutic use.